Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Noblejas-López MDM, Nieto-Jiménez C, Morcillo García S, Pérez-Peña J, Nuncia-Cantarero M, Andrés-Pretel F, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocana A.

Oncoimmunology. 2019 Jul 3;8(10):e1629780. doi: 10.1080/2162402X.2019.1629780. eCollection 2019.

PMID:
31646075
2.

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Noblejas-López MDM, Nieto-Jimenez C, Burgos M, Gómez-Juárez M, Montero JC, Esparís-Ogando A, Pandiella A, Galán-Moya EM, Ocaña A.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383. doi: 10.1186/s13046-019-1387-5.

3.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

4.

Mapping Bromodomains in breast cancer and association with clinical outcome.

Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, Győrffy B, Ocana A.

Sci Rep. 2019 Apr 5;9(1):5734. doi: 10.1038/s41598-019-41934-3.

5.

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Noblejas-López MDM, Morcillo-García S, Nieto-Jiménez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A.

PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.

6.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25.

7.

Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.

Nuncia-Cantarero M, Martinez-Canales S, Andrés-Pretel F, Santpere G, Ocaña A, Galan-Moya EM.

Breast Cancer Res Treat. 2018 Apr;168(3):613-623. doi: 10.1007/s10549-017-4652-3. Epub 2018 Jan 12.

8.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

9.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

10.

Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.

Tibau A, Díez-González L, Navarro B, Galán-Moya EM, Templeton AJ, Seruga B, Pandiella A, Amir E, Ocana A.

Mol Diagn Ther. 2017 Jun;21(3):337-343. doi: 10.1007/s40291-017-0267-y.

PMID:
28247182
11.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

12.

Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma.

Treps L, Edmond S, Harford-Wright E, Galan-Moya EM, Schmitt A, Azzi S, Citerne A, Bidère N, Ricard D, Gavard J.

Oncogene. 2016 May 19;35(20):2615-23. doi: 10.1038/onc.2015.317. Epub 2015 Sep 14.

PMID:
26364614
13.

The guanine exchange factor SWAP70 mediates vGPCR-induced endothelial plasticity.

Dwyer J, Azzi S, Leclair HM, Georges S, Carlotti A, Treps L, Galan-Moya EM, Alexia C, Dupin N, Bidère N, Gavard J.

Cell Commun Signal. 2015 Feb 15;13:11. doi: 10.1186/s12964-015-0090-1.

14.

Endothelial secreted factors suppress mitogen deprivation-induced autophagy and apoptosis in glioblastoma stem-like cells.

Galan-Moya EM, Treps L, Oliver L, Chneiweiss H, Vallette FM, Bidère N, Gavard J.

PLoS One. 2014 Mar 28;9(3):e93505. doi: 10.1371/journal.pone.0093505. eCollection 2014.

15.

Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2.

Dwyer J, Hebda JK, Le Guelte A, Galan-Moya EM, Smith SS, Azzi S, Bidere N, Gavard J.

PLoS One. 2012;7(9):e45562. doi: 10.1371/journal.pone.0045562. Epub 2012 Sep 20.

16.

Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation.

Le Guelte A, Galan-Moya EM, Dwyer J, Treps L, Kettler G, Hebda JK, Dubois S, Auffray C, Chneiweiss H, Bidere N, Gavard J.

J Cell Sci. 2012 Sep 1;125(Pt 17):4137-46. doi: 10.1242/jcs.108282. Epub 2012 Jun 8.

17.

Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.

Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, Varlet P, Devaux B, Soncin F, Gavard J, Junier MP, Chneiweiss H.

Stem Cells. 2012 May;30(5):845-53. doi: 10.1002/stem.1062.

18.

Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.

Galan-Moya EM, de la Cruz-Morcillo MA, Llanos Valero M, Callejas-Valera JL, Melgar-Rojas P, Hernadez Losa J, Salcedo M, Fernández-Aramburo A, Ramon y Cajal S, Sánchez-Prieto R.

PLoS One. 2011;6(12):e28406. doi: 10.1371/journal.pone.0028406. Epub 2011 Dec 2.

19.

P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.

de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R.

Oncogene. 2012 Mar 1;31(9):1073-85. doi: 10.1038/onc.2011.321. Epub 2011 Aug 15.

PMID:
21841826
20.

Feeding the hungry enemy: an endothelial recipe for glioma stem cells.

Galan-Moya EM, Gavard J.

Cell Cycle. 2011 Aug 1;10(15):2403-4. Epub 2011 Aug 1. No abstract available.

PMID:
21750405
21.

Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.

Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, Bidere N, Couraud PO, Scott MG, Junier MP, Chneiweiss H, Gavard J.

EMBO Rep. 2011 May;12(5):470-6. doi: 10.1038/embor.2011.39. Epub 2011 Apr 1.

22.

Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor.

Dwyer J, Le Guelte A, Galan Moya EM, Sumbal M, Carlotti A, Douguet L, Gutkind JS, Grange PA, Dupin N, Gavard J.

Oncogene. 2011 Jan 13;30(2):190-200. doi: 10.1038/onc.2010.411. Epub 2010 Sep 6.

PMID:
20818438
23.

PAKing up to the endothelium.

Galan Moya EM, Le Guelte A, Gavard J.

Cell Signal. 2009 Dec;21(12):1727-37. doi: 10.1016/j.cellsig.2009.08.006. Epub 2009 Aug 29. Review.

24.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R.

PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124.

25.

c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.

Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramírez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Ramón y Cajal S, Silvio Gutkind J, Sánchez-Prieto R.

Int J Cancer. 2008 Jan 15;122(2):289-97.

26.

Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.

Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernández Losa J, Parada Cobo C, Galán Moya EM, Gayoso Cruz J, Melo JV, Ramón y Cajal S, Sánchez-Prieto R.

Biochem J. 2005 Apr 1;387(Pt 1):231-8.

Supplemental Content

Loading ...
Support Center